This compound has a stronger human clinical evidence base than typical research peptides, but it still requires clinician oversight and approved-use context.
Overview
Semaglutide is a GLP-1 receptor agonist and one of the few peptides in this library that is FDA-approved and prescription-available (as Ozempic, Wegovy, and oral Rybelsus). It has driven much of the mainstream attention on peptides.
How It's Thought to Work
Semaglutide mimics GLP-1, a gut hormone that stimulates insulin release, slows gastric emptying, and reduces appetite by acting on receptors in the brain and pancreas.
What the Research Says
Supported by large, well-designed human clinical trials for type 2 diabetes (SUSTAIN) and weight management (STEP), plus cardiovascular outcome data (SELECT). This is among the most robustly studied compounds in the peptide conversation.
Key studies to start with
What's Coming Up Next? The Physiology of Gastroparesis and GLP-1 Agonists
Annual review of physiology · 2026 Nov 6
PubMedExploring time-varying cardiovascular effects of GLP-1 receptor agonists: A multi-state network meta-analysis of cardiovascular outcome trials
Diabetes research and clinical practice · 2026 Nov 6
PubMedSemaglutide (Wegovy) for secondary cardiovascular prevention in adults with an elevated BMI
Drug and therapeutics bulletin · 2026 Nov 6
Regulatory & Legal Status
FDA-approved and prescription-only for approved indications. Compounded and counterfeit versions are a known safety concern.
Safety Considerations
Common side effects include nausea and GI upset; there are important warnings and contraindications. Use only under a prescribing clinician's care.